James Garnett, MD
Interventional Cardiology · Richmond, VANPI 1922125053
Payments from drug & device makers
Across 355 payments — averaging $53.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Edwards Lifesciences$5K
- W. L. Gore & Associates, Inc.$4K
- Medtronic$844
- Novartis$523
- Boston Scientific$326
- plus $2K from 31 others
What the payments were for
- Consulting fees$120%
- Travel & lodging$6,64835%
- Food & beverage$12,36565%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 100 | $5,605 |
| Edwards Lifesciences | 63 | $4,860 |
| W. L. Gore & Associates, Inc. | 28 | $4,396 |
| Medtronic(2 entities) | 11 | $844 |
| Novartis | 27 | $523 |
| Boston Scientific | 13 | $326 |
| Angiodynamics, Inc. | 9 | $246 |
| Amgen | 13 | $239 |
| Penumbra, Inc. | 3 | $200 |
| Boehringer Ingelheim | 12 | $192 |
| Pfizer | 11 | $170 |
| Johnson & Johnson | 10 | $168 |
| Sanofi-aventis U.S. LLC | 8 | $138 |
| Philips North America LLC | 4 | $116 |
| E.r. Squibb & Sons, L.L.C. | 6 | $102 |
| Shockwave Medical, Inc | 1 | $100 |
| Atricure, Inc. | 3 | $94 |
| Cardiva Medical, Inc. | 3 | $94 |
| Cordis US CORP. | 1 | $65 |
| Biosense Webster, Inc. | 3 | $62 |
| Cardiovascular Systems Inc. | 4 | $60 |
| Impulse Dynamics (USA) Inc. | 1 | $46 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Novo Nordisk | 2 | $39 |
| Scpharmaceuticals Inc. | 2 | $39 |
| Ancora Heart, Inc. | 1 | $34 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Sanofi | 1 | $22 |
| Bayer | 1 | $19 |
| Abiomed | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Merck | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Livanova USA, Inc. | 1 | $14 |
| Itamar Medical Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,955
- GORE CARDIOFORM Septal Occluder$2,593
- CARDIOFORM Septal Occluder$1,259
- MitraClip$836
- SAPIEN 3 Ultra RESILIA$464
- MitraClip System$440
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$306
- COREVALVE EVOLUT R$281
- Optis Coronary Imaging System$238
- Resolute$215
- NAVITOR$164
- Indigo System$148
- COROFLOW$141
- Xience Sierra Coronary Stent System$141
- AMPLATZER Occluders$129
- XIENCE SIERRA$126
- Mitra Clip system$124
- OPTIS$118
- AMPLATZER TALISMAN$117
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$100
How this compares
$19,025 in reported general payments places this provider in the 70th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 317 | $298,389 |
| EntrestoSacubitril/Valsartan | 150 | $159,321 |
| XareltoRivaroxaban | 91 | $125,228 |
| FarxigaDapagliflozin Propanediol | 121 | $101,250 |
| Repatha SureclickEvolocumab | 44 | $52,391 |
| BrilintaTicagrelor | 29 | $19,503 |
| Metoprolol Succinate | 500 | $5,213 |
| Atorvastatin Calcium | 316 | $2,785 |
| Flecainide Acetate | 49 | $2,669 |
| Losartan Potassium | 289 | $2,640 |
| Ezetimibe | 74 | $1,724 |
| Prasugrel Hcl | 24 | $1,661 |
| ClopidogrelClopidogrel Bisulfate | 162 | $1,588 |
| Bumetanide | 48 | $1,490 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 120 | $1,363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $170 | $298,389317 claims |
| NovartisEntresto | $523 | $159,321150 claims |
| Johnson & JohnsonXarelto | $168 | $125,22891 claims |
| AstraZenecaFarxiga, Brilinta | $16 | $120,752150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Richmond
- Gansevoort DunningtonRichmond$440K
- Rakesh JainRichmond$331K
- Nayef AbouzakiRichmond$250K
- Ion JovinRichmond$116K
- Michael ArcareseRichmond$88K
- Matthew ChungRichmond$75K
- Zachary GertzRichmond$36K
- Ashwani KumarRichmond$35K
- Brinder KandaRichmond$34K
- Barbara LawsonRichmond$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.